1. Öztürk R. Grip ( Influenza ): Tarihçe - Etyoloji -Patogenez . Hipokrat Dergisi 44: 8 - 9; 1995
2. Aktas F. Influenza ( Grip ). in: Topçu A. W., Söyletir G, Doganay M, eds. infeksiyon Hastaliklari. 1. baski. istanbul: Nobel Tip Kitabevleri Ltd. Sti; 1996: 367 -369
3. Heilman C, Montagne J. R. Influenza: Status and Prospects for Its Prevention, Therapy, and Control. Pediat Clin North Am 37 ( 3 ): 669 - 681; 1990
4. Hall C.B. Influenza. Pediatrics 79: 564 - 566; 1987
5.
ÖztürkR
. 1918-1919 Grip Pandemisi. Cerrahpaşa Tıp
FakDerg20:479-485; 1989
6. Kanra G, Ecevit Z. Influenza Asisi. Katki Pediatri
Dergisi 2: 122-126; 1994
7. Maucher J. M., Gambert S. T. Cost - Effective Analysis of Influenza Vaccination in the Elderly. Age 13: 81 -85; 1990
8. Webster R. G., Bean W. J., Gorman O. T et al.
Evolution and Ecology of Influenza A Viruses.
Microbiol Rev 56 ( 1 ): 152-179; 1992
9. Akan E. Genel ve Özel Viroloji. 2. Baski. Ankara:
Türkiye Klinikleri Yayinevi, 1989, 333 - 352
10. Serter D. Virüs, Riketsiya Ve Klamidya Hastaliklari.
Izmir: Nobel Tip Kitapevi, 1997, 278 - 290
11. Davis B, Dulbecco R., Eisen H.s Ginsberg H.S., eds. Microbiology 4th. ed. Philadelphia: J.B. Lippincott
Company; 1990: 985 - 1005
12. Avalos R. T., Yu Z., Nayak D. P. Association of Influenza Virus NP and M, Proteins with Cellular Cytoskeletal Elements in Influenza Virus - Infected
Cells. J Virol 71( 4 ): 2947 - 2958; 1997
13. Başaran G. Grip: Klinik, Komplikasyonlar ve Prognoz.
Hipokrat Dergisi. 44: 12-16; 1995
105
14. Callan R J., Hartmann F. A., West S. E et al. Cleavage of Influenza A Virus HI Hemagglutinin by Swine Respiratory Bacterial Proteases. J Virol 71: 7579 -7585; 1997
15. Douglas R. G. Drug Therapy: Prophylaxis and Treatment of Influenza. New Engl J Med 322 ( 7 ): 443 -450; 1990
16. Grist R.N., Reid D. Influenza Immunization. Immunization in Practice.
15: 1068 - 1074; 1987
17. Wilson R. Influenza Vaccination. Thorax 49: 1079 -
1080; 1994
18. Chaloupka I, Schuler A., Marschall M et al.
Comparative Analysis of Six European Influenza Vaccines. Eur J Clin Microbiol Infect Dis, 15: 121 -
127; 1996
19. Berktas B. M. Influenza Asilamasi. Microbiyol Biilt
28:392-403; 1994
20. U. S. Department of Health and Human Services, Public Health Service - Centers for Disease Control and Prevention. Prevention and Control of Influenza: Recommendations of the Advisory Committe on Immunization Practices ( ACIP ). Morb Mortal Wkly Rep ( MMWR ) 46 ( RR-9 ): 1 -16; 1997
21. Plotkin A.S. Vaccination in the 21st Century. J Infect
Dis 168:29-37; 1993
22. U. S. Department of Health and Human Serv;;es, Public Health Service - Centers for Disease Control and Prevention. Prevention and Control of Influenza: Recommendations of the Advisory Committe on Immunization Practices (ACIP ). Implementation of the Medicare Influenza Vaccination Benefit - United States, 1993. Morb Mortal Wkly Rep ( MMWR ) 43 (
42): 771 -773; 1994
23. Gardner P., Schaffner W. Immunization of Adults. New
Engl J Med 328 ( 17 ): 1252 - 1258; 1993
24. Mostow S. R., Cate T. R., Ruben F. L. Prevention of Influenza and Pneumonia. Am Rev Respir Dis 142:
487-488; 1990
25. Nichol K. L., Margolis K. L., Wuorenma R. N. J et al.
The Efficacy and Cost Effectiveness of Vaccination Against Influenza Among Elderly Persons Living in the
Community. New Engl J Med 331 ( 12 ):778 - 784; 1994
26. Simonsen L., Clarke M. J., Schonberger L. B et al. Pandemic versus Epidemic Influenza Mortality: A Pattern of Changing Age Distrubition. J Infect Dis 178:
53-60; 1998
27. Schoenbaum S. C. Economic Impact of Influenza. The Individual's Perspective. Am J Med 19 ( 82 - 6A ): 26 -
30; 1987
28. Halperin W., Weiss W., Airman R et al. A Comparison of the Intradermal and Subcutaneous Routes of Influenza Vaccination with A / New Jersey / 76 ( Swine Flu ) and A / Victoria / 75: Report of a Study and Review of the Literatür. Am J Public Health 69 ( 12 ):
1247 - 1251;197929. Bclshe R. B., Swierkosz E. M., Anderson E. L et al. Immunization of Infants and Young Children with Live Attenuated Trivalan Cold -Recombinant Influenza A H,N,, H,N2 and B Vaccine. J Infect Dis 165:727-732; 1992
30. Glathe H., Lange W. Influenza Vaccination in Older Patients. Immunogenicity, Epidemiology and Available
Agents. Drugs Aging 6 ( 5 ): 368 - 387; 1995
31. Tamura S. I., Kurata H., Funato H et al. Protection Against Influenza Virus Infection by a Two- Dose Regimen of Nasal Vaccination Using Vaccines Combined with Cholera Toxin B Subunit. Vaccine 7: 314-320; 1989
32. Palache A.M. Influenza Vaccines. A Reappraisal of
Their Use. Drugs 54 ( 6 ): 841 - 856; 1997
33. Ganguly R., Cameron D. Factors Affecting Immunization Rate in a Cohort of Elderly Veterans: A Retrospective Pilot Study of Influenza Vaccine
Compliance. Vaccine 7: 462 - 464; 1989
34. Atmar R. L., Keitel W. A., Cate T. R et al. Comparison
of Trivalent Cold - Adapted Recombinant ( CR ) Influenza Virus Vaccine with Monovalent CR Vaccines
in Healthy Unselected Adults. .1 Infect Dis 172: 253 -257;1995
35. Groothuis J. R., Levin, M. J., Rabalais G. P et al.
Immunization of High - Risk Infants Younger Than 18 Months of Age with Split - Product Influenza Vaccine.
Pediatrics 87 ( 6 ): 823 - 828; 1991
36. Fedson D. S., Wajda A., Nicol J. P et al. Clinical
Effectiveness of Influenza Vaccination in Manitoba.
JAMA 270 ( 16): 1956- 1961; 1993
37. Nichol K. L., Lind A., Margolis K. L et al. The
Effectiveness of Vaccination Against Influenza in Healthy, Working Adults. New Engl J Med 333 (14):
890-893; 1995
38. Grotto I., Mandel Y., Green M. S et al. Influenza
Vaccine Efficacy in Young, Healthy Adults. Clin Infect Dis 26: 913-917; 1998
39. Gross A. P., Hermogenes A. W., Sacks H. S et al. The Efficacy of Influenza Vaccine in Elderly Persons. A Meta - Analysis and Review of the Literature. Ann
Intern Med 123: 518 - 527; 1995
40. Mullooly J. P., Bennett M. D., Hornbrook M. C et al.
Influenza Vaccination Programs for Elderly Persons: Cost - Effectiveness in a Health Maintenance Organization. Ann Intern Med 121: 947 - 952; 1994
41. Nicholson K.G., Snacken R., Palache A. M. Influenza Immunization Policies in Europe and the United States.
Vaccine 13(4)365-369; 1995
42. Karl A. B., Cox R. J., Olofsson J et al. Parenteral
Influenza Vaccination Induces a Rapid Systemic and Local Immune Response. J Infect Dis 171: 198 - 203;
1995
43. Brokstand K. A., Cox R. J., Oxford J. S et al. IgA, IgA
Subclasses, and Secretory Component Levels in Oral Fluid Collected from Subjects after Parenteral Influenza
106
Vaccination. J Infect Dis 171: 1072- 1074; 1995
44. Cox R. J., Brokstad K. A., Zuckerman M. A et al. An Early Humoral Immune Response in Peripheral Blood Following Parenteral Inactivated Influenza Vaccination. Vaccine 12(11): 993 - 999; 1994
45. Bender B. S., Small P. A. Heterotypic Immune Mice Lose Protection Against Influenza Virus Infection With
Senescence. J Infect Dis 168: 873 - 880; 1993
46. El-Madhun A. S., Cox R. J., Soreide A et al. Systemic and Mucosal Immune Responses in Young Children and Adults after Parenteral Influenza Vaccination. J Infect Dis 178: 933 - 939; 1998
47. Blumberg E. A., Albano C, Pruett T et al. The
Immunogenicity of Influenza Virus Vaccine in Solid Organ Transplant Recipients. Clin Infect Dis 22: 295 -
302; 1996
48. Swierkosz E. M., Newman F. K., Anderson E. L et al. Multidose, Live Attenuated, Cold - Recombinant, Trivalent Influenza Vaccine in Infants and Young
Children. J Infect Dis 169: 1121 - 1124; 1994
49. Knowles G. K., Taylor P., Warwick M. T. A
Comparison of Antibody Responses to Admune Inactivated Influenza Vaccine In Serum and Respiratory Secretions of Healthy Non - Smokers, Healthy Cigarette - Smokers and Patients with Chronic
Bronchitis. B J Dis Chest 75: 283 - 290; 1981
50. Brokstad K. A., Cox R. J., Major D et al. Cross -Reaction but no Avidity Change of the Serum Antibody Response After Influenza Vaccination. Vaccine 13(16 ): 1522-1528;1995
51. Gotoff R., Tamura M., Janus J et al. Primary Influenza
A Virus Infection Induces Cross - Reactive Antibodies that Enhances Uptake of Virus into Fc Reseptör -
Bearing Cells. J Infect Dis 169: 200 - 203; 1994
52. Strassburg M. A. Influenza in the Elderly: Report of an
Outbreak and a Rewiev of Vaccine Effectiveness
Report. Vaccine 4: 38 - 44; 1986
53. German M. F., Taillandier J., Mathieu D et al. Usefulness of Influenza Vaccination in the Elderly.
Bromed & Pharmacother 45: 29 - 32; 1991
54. Diepersloot R. J. A. Humoral Immune Response and Delayed Type Hypersensitivity to Influenza Vaccine in Patients with Diabetes Mellitus. Diabetologia 30: 397 -
401; 1987
55. Shildt R. A., Luedke D. W., Kasai G et al. Antibody
Response to Influenza Immunization in Adult Patients
with Malignant Disease. Cancer 44: 1629 - 1635; 1979
56. Gross P. A., Gould A. L., Brown A. E. Effect of Cancer Chemotherapy on the Immune Response to Influenza Virus Vaccine: Review of Published Studies. Rev
Infect Dis 7: 613 -618; 1985
57. Whimbey E., Elting L., Couch R et al. Antibody Response to a Two - Dose Influenza Vaccine Regimen in Adult Lymphoma Patients on Chemotherapy. Eur J
Clin Microbiol Infect Dis 12 ( 10 ): 78 - 82; 1993
58. Nelson K. E., Clements M. L., Miotti P et al. The
Influence of Human Immunodeficiency Virus ( HIV ) Infection on Antibody Responses to Influenza Vaccine.
Ann Intern Med 109: 383-388; 1988
59. Rautenberg P., Teifke I., Schlegelberger T et al. Influenza Subtype -Specific IgA, IgM, and IgG Responses in Patients on Hemodialysis after Influenza
Vaccination. Infection 16: 322 - 328; 1988
60. Descamps B., Chatenoud L. Effects on the Immune Response. In: Cameron S, Davison A. M., Grtinfeld J.
P., Kerr D. N.s Ritz E., Winearls C. G., eds. Oxford
Textbook of Clinical Nephrology. 2"d ed. New York:
Oxford University Press; 1998: 1982- 1989
61. Johnson D. W., Fleming S. J. The Use of Vaccines in
Renal Failure. Clin Pharmacokinet 22 ( 6 ): 434 - 446; 1992
62. Kreft B., Klouche M., Kreft R et al. Low Efficiency of Active Immunization Against Diphtheria in Chronic
Hemodialysis Patients. Kidney Int 52: 212 - 216; 1997
63. Remuzzi G., Rossi E. C. Hematologic Consequences of Renal Failure. In: Brenner B. M., ed. The Kidney. 5th
ed. USA: W. B. Saunders Company; 1996: 2170 - 2186
64. Bargman J. M., Oreopulos D. G. Complications Other Than Peritonitis or Those Related to the Catheter and the Fate of Uremic Organ Dysfunction in Patients Receiving Peritoneal Dialysis. In: Nolph K. D., ed. Peritoneal Dialysis. 3rd ed. Netherlands: Kluwer
Academic Publishers; 1990: 289-310
65.
Apaydı
n S. Böbrek Transplantasyonundan Sonra Gelişen Enfeksiyon Komplikasyonları. in: Erek E., ed., Böbrek Transplantasyonu. 4. baskı. İstanbul: Nobel Tıp Kitabevleri Ltd. Şti.; 1994: 364 - 386
66. Peter W. L., Clark J. L., Levos O. M. Drug Therapy in Haemodialysis Patients. Special Considerations in the
Elderly. Drugs Aging 12 ( 6 ) 441 - 459; 1998
67. Fivush B. A., Neu A. M. Immunization Guidelines for Pediatric Renal Disease. Semin Nephrol 18(3): 256 -
263; 1998
68. Fleming S . J. , Moran D. M., Cooksley W. G et al.
Poor Response to a Recombinant Hepatitis B Vaccine
in Dialysis Patients. J Infect 22 ( 3 ): 251 - 257; 1991
69.
Jilkov
a E., Jilek D., Bitterova Z et al. Hepatitis B Vaccination in Patients with Chronic Renal Failure.
Epidemiol Mikrobiol Immunol 46 ( 4 ): 135 - 139; 1997
70. Rault R., Freed B., Nespor S et al. Efficacy of Different
Hepatitis B Vaccination Strategies in Patients
Receiving Hemodialysis. ASAIO J 41( 3 ): 717 - 719; 1995
71. Mitwalli A. Responsiveness to Hepatitis B Vaccine in Immunocompromised Patients by Doubling the Dose
Scheduling. Nephron 73 ( 3 ): 417 - 420; 1996
72. Palache A. M., Beyer W. E., Luchters G et al. Influenza Vaccines: The Effect of Vaccine Dose on Antibody Response in Primed Populations During the Ongoing Interpandemic Period. A Review of the Literature.
Vaccine 11 ( 9 ): 892 - 908; 1993
107
Thank you for copying data from http://www.arastirmax.com
